How'd you fix McKesson's revenue issues in 2026?
Curated by Kory White · Fractional CRO, CRO Syndicate
Direct Answer: McKesson's real issue isn't revenue growth—US Pharma is up 18% YoY to $327.7B (fiscal 2025, 10-K). The problem is margin dilution from GLP-1 scale and Medical-Surgical Solutions near-flatline (1% growth to $11.4B). A CRO would fix this via: (1) Oncology + specialty channel capture (Florida Cancer Specialists deal model), (2) Direct-to-pharmacy AI/automation to offset GLP-1 low-margin mix, (3) Medical-Surgical spinoff acceleration + private equity buyout premium, (4) Enterprise automation via Salesforce Health Cloud + Veeva CRM to reduce MSS friction, (5) Surgical distribution margin recovery via Pavilion playbook (value engineering → command center).
Bottom line: Revenue problem is actually a margin problem masquerading as growth—McKesson has oligopoly volume but needs to fix unit economics.
What's Actually Broken
Segment Reality (Fiscal 2025 10-K):
- US Pharmaceutical: $327.7B, +18% YoY — Volume growth is robust (GLP-1 tailwind from Ozempic/Zepbound distribution, +$14B in Q3 2026 alone per Morningstar)
- Medical-Surgical Solutions: $11.4B, +1% YoY — Post-COVID vaccine distribution cliff; kitting business under pressure; primary care growth insufficient to offset
- Prescription Technology Solutions: $5.22B, +9% YoY — oncology logistics + affordability tech growing, but dwarfed by pharma scale
The Real Margin Trap: GLP-1 drugs are branded, high-volume, lower-margin. Finterra Capital (Feb 2026) flagged: "GLP-1 products fuel robust sales growth, but margin headwinds." McKesson distributes at 1–2% gross margin on commodity generics; GLP-1 is maybe 3–5% but at 10x volume.
Net result: gross margin compression as mix shifts. Operating leverage doesn't save you when you're distributing more units at lower $/unit.
Competitive Pressure Intensifying:
- Cencora (ABG spin): 34.56% market share Q2 2025, $294B revenue, moving into oncology + specialty via acquisitions (Retina Consultants of America, Jan 2025 → +$0.35 EPS)
- Cardinal Health: 24.24% market share, $3.9B specialty acquisitions, same oncology-diabetes play
- McKesson: 41.21% market share, largest, but under siege. Oligopoly = stable, but zero pricing power on high-volume GLP-1 (price is set by PBMs and pharma).
The Spinoff Shadow: May 2025, McKesson announced intent to separate Medical-Surgical Solutions (2027 target). Market is already pricing in: "MSS is burden, pharma-focused company = multiple expansion." But pre-spinoff, MSS drag is real, and CHRO is watching burn.
2026 Fix Playbook (5 Moves)
Move 1: Oncology Channel Capture (Pavilion Playbook)
Problem: Oncology is high-volume, high-margin specialty; McKesson owns Florida Cancer Specialists (integrated 2025) but isn't fully monetizing it. Cardinal and Cencora are both hunting here.
Fix: Use Pavilion's sales management playbook to build McKesson's "Oncology Command Center"—a dedicated distribution + staffing + reporting hub for cancer practices.
- Recruit oncology-specialized AEs (Pavilion trains on specialty pharma dynamics, prior auth dynamics, P&T tactics)
- Build 1-page "oncology rep card" for each major drug class (checkpoint inhibitors, targeted therapy, support drugs)
- Deploy Salesforce Health Cloud to track practice P&T preferences, reorder cadence, compliance metrics
- Target: Convert 1,000+ community oncology practices into locked-in McKesson accounts (switchover cost = new IT setup)
- Revenue upside: +$2–3B annually in specialty pharma volume at 4–6% margin (vs. 2–3% on generics)
Move 2: Medical-Surgical Solutions Margin Fix via Force Management + Salesforce
Problem: MSS grew 1% YoY. Kitting business is commodity. Primary care growth is tepid. Sales team isn't selling; they're order-taking.
Fix: Install Force Management's 6-week "COMMAND" playbook (Situation/Complication → Implication → Need Payoff) to convert MSS from transactional to consultative.
- Retrain 200+ MSS field reps to sell value bundles (surgical packs + delivery logistics + inventory management) vs. SKUs
- Salesforce Health Cloud integration: Real-time surgical volume forecasting, bundle recommendation engine ("Based on your Q2 hip replacements, here's your Q3 pack mix")
- Build surgeon/OR manager business reviews (quarterly): Show them supply cost %, compliance risk, competitor benchmarks
- Target: Increase MSS attach rates (cross-sell logistics + compliance to existing surgical customers) by 15%, offsetting volume softness
- Revenue upside: +$500M–$1B annually from higher-margin services + bundle lock-in
Move 3: GLP-1 Mix Optimization via AI/Automation (Klue + Veeva CRM)
Problem: GLP-1 margins are thin. McKesson is distributing massive volume but losing leverage to Amazon Pharmacy, direct-to-consumer, and PBM-owned entities.
Fix: Use Klue (competitive intelligence) to track PBM formulary changes, pharmacy switching patterns, and DTC player moves. Then deploy Veeva CRM (pharma-native) to:
- Map every pharmacy's GLP-1 dispensing mix (Novo Nordisk vs. Eli Lilly vs. Generics horizon)
- Identify pharmacies vulnerable to DTC leakage (low Ozempic fill rates = likely Ro/GoodRx leakage)
- Deploy targeted outreach to recapture with rebate analytics + compliance programs
- Automation: API integration with pharmacy POS systems to flag margin-eroding moves in real-time
- Target: Recapture $1–2B in GLP-1 volume from DTC leakage; negotiate 25bps margin uplift via value-add (compliance data, dispensing tech)
Move 4: Bridge Group Sales Machine for Enterprise Clients
Problem: McKesson has hospital system + large pharmacy chains as customers, but sales motion is creaky. Bridge Group specializes in complex B2B sales to healthcare systems.
Fix: Deploy Bridge Group's "Demand Gen Inside Sales" playbook to McKesson's enterprise channel:
- Hire 50 inside sales reps (fully ramped cost: $12–15M annually)
- Target: Consolidate fragmented buying across hospital networks (hospital A buys from McKesson, hospital B from Cencora, hospital C mixed) → single master agreement
- Use Veeva CRM to track hospital formulary + supply chain initiatives; tie to value (cost reduction, OR efficiency, staff retention)
- Sales target: $5–10B in consolidated enterprise agreements at 10–25bps margin uplift
Move 5: Medical-Surgical Spinoff Acceleration (Set Up for Sale)
Problem: MSS spinoff is 2027, but board + investor story is weak. Pre-spinoff, MSS is dragging enterprise value.
Fix: Bring in Definitive Healthcare data layer to map every MSS customer (hospital system, GPO, ambulatory surgery center) and build customer health scoring:
- Which MSS customers are at risk of switching? (Competitor engagement, low utilization, margin pressure)
- Which are defensible? (High switching cost, high customer satisfaction, strategic partnership)
- Build "MSS Separation Readiness" scorecard: IT systems, compliance, customer concentration, margin profile
- Hand to private equity / strategic buyer with crystal-clear unit economics → $2–3B+ valuation premium vs. Dragging it out
- Use separation proceeds to fund Move 1–4 (oncology pivot, MSS transformation, GLP-1 defense, enterprise sales)
👉 Quick Call with Kory White, Fractional CRO · See Kory on LinkedIn · CRO Syndicate
Fix in Table Form
| Move | Lever | Timeline | Cost | Upside |
|---|---|---|---|---|
| 1: Oncology | Pavilion + Salesforce Health Cloud | 6–9 months | $15M (recruiting, training, tech) | +$2–3B specialty pharma @ 5% margin |
| 2: MSS Sales | Force Management + Veeva CRM | 4–6 months | $25M (training, tech, reps) | +$500M–1B bundle attach @ 8% margin |
| 3: GLP-1 Defense | Klue + Veeva + Pharmacy API | 3–4 months | $8M (data, tech, ops) | Recapture $1–2B @ +25bps margin |
| 4: Enterprise Sales | Bridge Group playbook | 6–9 months | $12–15M annually | $5–10B consolidation @ +10–25bps |
| 5: MSS Spinoff | Definitive Healthcare + separations | 12 months | $20M (consulting, tech stack split) | $2–3B+ acquisition premium, free cash to reinvest |
| TOTAL | ~$80–90M year 1 | ~$10–16B revenue uplift @ 2–5% margin expansion |
One Mermaid: McKesson Revenue Flywheel Fix
How I'd Partner With The CHRO Week 1
Monday 9am: Listening & Reality Check
- Deep dive on actual customer churn by segment (Klue + Salesforce data pull)
- Sales productivity by motion (enterprise vs. Transactional vs. Specialty)
- Which MSS customers are "at-risk"?
- What is McKesson's current GLP-1 margin floor? (vs. Cencora / Cardinal benchmarks)
- Org structure: How many field reps by segment? Sales management span? Tech stack?
Tuesday: Wall of Truth (Sales Ops + Finance)
- Sales comp plan by motion (commissions incentivizing margin, volume, or both?)
- AE productivity by segment (Oncology AEs should earn 1.5x more if margin is 5x higher)
- MSS sales team churn rates? (If >20%, sales motion is broken, not product)
- Veeva CRM / Salesforce readiness (McKesson may have legacy systems; true cost of tech stack = $40–80M)
Wednesday: Pilots & Proof of Concept
- Week 1 Oncology pilot: Select 1 metro (Charlotte, Phoenix, Dallas). Recruit 2–3 Pavilion-trained AEs. Target 20 community cancer practices for Salesforce Health Cloud + preferred ordering. Goal: +$50M volume in 90 days, margin data (baseline vs. Optimized).
- Week 1 MSS pilot: Select 1 hospital system (e.g., HCA, Ascension, Cleveland Clinic). Run Force Management half-day (C-suite, 3 VPs, 5 field reps). Test consultative sales model on 10 surgical suites. Goal: Identify 2–3 high-margin service bundles (surgical supply management, compliance, staffing).
- GLP-1 defense data pull: Klue competitive analysis + Veeva pharmacy mix map. How many McKesson pharmacies are losing GLP-1 fill share? DTC leakage risk by geography?
Thursday: Org Readiness & Hiring Plan
- If MSS margin fix requires 50 new inside-sales reps, recruiting timeline = 4–6 months. Start now.
- If Oncology pivot requires 30 specialized AEs (target: recruiting from pharma sales, specialty distributors, Cencora/Cardinal incumbents), offer: base $120–150k, ramp-up bonus, override on margin (not just volume).
- Do we need VP-level hires? (CMO for oncology, SVP for enterprise sales?) Or can we backfill talent from within?
Friday: Board Narrative & Separation Timeline
- Spinoff is 2027, but runway is NOW. What does Definitive Healthcare tell us about MSS unit economics? If margins are 6%, is it separable? If 3%, do we need 18 months of margin recovery first?
- If we acquire Definitive Healthcare data + run separations playbook now, we de-risk the spinoff, potentially move it to 2026H2 (early exit for activist investors holding Cencora / Cardinal stock waiting for industry consolidation).
Key Week 1 Ask:
- Sales data access: Monthly rev by segment, by customer segment (community pharmacy, hospital, oncology practice, GPO), by AE
- Org chart: Sales org, marketing, ops, finance (to staffing plan the 5 levers)
- Customer health data: Churn, NPS, expand/contract trends by segment
- Comp plan: Current structure (margin vs. Volume incentive misalignment is likely culprit for MSS slowdown)
FAQ
Why does the article call McKesson's situation a margin problem, not a growth problem? US Pharmaceutical revenue is up 18% YoY to $327.7B (fiscal 2025), so volume is robust thanks to the GLP-1 tailwind from Ozempic and Zepbound distribution. The trouble is margin dilution: McKesson distributes generics at 1–2% gross margin and GLP-1 at maybe 3–5% but at 10x volume, so the mix shift compresses gross margin even as the top line grows.
How does the Oncology Command Center play work? Move 1 uses Pavilion's sales management playbook to build a dedicated distribution, staffing, and reporting hub for cancer practices, leveraging the Florida Cancer Specialists asset that McKesson integrated in 2025. It recruits oncology-specialized AEs, builds 1-page rep cards per drug class, and deploys Salesforce Health Cloud, targeting 1,000+ locked-in community oncology practices and $2–3B in specialty volume at 4–6% margin.
What is broken in Medical-Surgical Solutions and how is it fixed? MSS grew only 1% YoY to $11.4B because the kitting business is commoditized and the sales team is order-taking rather than selling. Move 2 installs Force Management's 6-week "COMMAND" playbook to retrain 200+ field reps to sell value bundles plus Salesforce Health Cloud forecasting, targeting a 15% lift in attach rates for $500M–$1B in higher-margin services.
How does the playbook defend GLP-1 volume against DTC leakage? Move 3 uses Klue to track PBM formulary changes and DTC player moves, then deploys Veeva CRM to map each pharmacy's GLP-1 dispensing mix and flag pharmacies vulnerable to Ro/GoodRx leakage. With targeted rebate and compliance outreach plus pharmacy-POS API integration, it targets recapturing $1–2B in GLP-1 volume and a 25 bps margin uplift.
Where does McKesson stand competitively against Cencora and Cardinal Health? McKesson holds the largest 41.21% market share, ahead of Cencora at 34.56% ($294B revenue) and Cardinal Health at 24.24%. But both rivals are pushing into oncology and specialty via acquisitions (Cencora's Retina Consultants of America, Cardinal's $3.9B specialty deals), and McKesson has zero pricing power on high-volume GLP-1 since price is set by PBMs and pharma.
Bottom line
McKesson's "revenue issues" are actually a margin and channel mix problem. US Pharma growth is real (18% YoY), but GLP-1 volume scales the company without scaling profit. Medical-Surgical has hit a wall (post-COVID cliff + competitive leakage).
A CRO's playbook is: (1) defend GLP-1 margin via PBM + pharmacy intelligence (Klue, Veeva), (2) capture high-margin oncology via Pavilion sales discipline, (3) fix MSS consultative motion via Force Management, (4) lock enterprise via inside-sales consolidation (Bridge Group), (5) de-risk spinoff via Definitive Healthcare customer mapping.
Win condition: $10–16B revenue uplift over 18 months, 2–5% margin expansion, pure-play pharma multiple on 2027 spinoff. This is a $500M–$1B annual EBITDA upside swing.
TAGS: mckesson,revenue-fix,turnaround,cro-candidate-pitch,executive-outreach,healthcare,distribution,pharmaceutical,glp-1,oncology,margin-expansion,sales-operations,spinoff,gpo,hospital-systems,specialty-pharma,pavilion,force-management,bridge-group,klue,veeva-crm,salesforce-health-cloud,definitive-healthcare